REGN•benzinga•
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease
Summary
Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a decision expected by April 2025.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 15, 2024 by benzinga